Key data for Vyxeos Liposomal from cohorts in England, France, Italy and Germany in the context of Study 301 results. All in a handy format you can access offline.
This site is intended for United Kingdom/Ireland healthcare professionals
Acute Myeloid Leukaemia Resources
Welcome to the resource centre.
You can filter the resources by topic and category to find those that best match your needs.
Selecting a resource will open the material in a new tab.
Filter
- Explore now
-
Vyxeos Liposomal: An overview of real-world evidence from four European studiesTopics
Real-world Data Safety Vyxeos Liposomal Data
UK-VYX-2100252 | January 2022
-
12 mins
Lancet J, et al. Lancet Haematol. 2021: The 5-year analysis of Study 301In this final analysis of the Phase III pivotal trial for Vyxeos Liposomal, the authors present the OS outcomes for the overall ITT population, as well as a breakdown of the results by patient age, cytogentic profile, prior HMA exposure, consolidation therapy, and more.
Topics
Cytogenetics Safety Vyxeos Liposomal Data
UK-VYX-2100177 | September 2021
-
10 mins
The Impact of Vyxeos Liposomal on patients with t-AML and AML-MRC – The French ExperienceExplore the outcomes of 103 patients treated with Vyxeos Liposomal in this French multicentric cohort. The study presents multiple efficacy endpoints, including MRD-negativity prior to HSCT, and contributes to the current understanding of the Vyxeos Liposomal tolerability profile.
Topics
Safety Vyxeos Liposomal Data
UK-VYX-2100176 | September 2021
-
9 mins
Guolo F, et al. Blood Cancer J. 2020: Treatment with Vyxeos Liposomal in a compassionate use programDiscover the full outcomes of this multicentre cohort in Italy, where 71 patients were treated with Vyxeos Liposomal showing a 12-month OS of 68.6% and a manageable adverse events profile.1
- Guolo F, et al. Blood Cancer J 2020;10.1038/s41408-020-00361-8
Topics
Safety Vyxeos Liposomal Data
UK-VYX-2100175 | September 2021
-
3 mins
Vyxeos Liposomal: Licence and Indication cardAll the details you need on the indication and reimbursement status of Vyxeos Liposomal are available at a glance in this card.
Topics
Practicalities
UK-VYX-2100126 | May 2021
-
1 min
The American Society of Hematology (ASH) Guidelines: A Summary by Dr Priyanka MehtaA brief summary from Dr Priyanka Mehta of the latest American Society of Hematology (ASH) recommendations for the treatment of older patients with AML.
Topics
Practicalities Safety
UK-VYX-2100030 | March 2021
-
3 mins
Selecting the Right Treatment for Your Patient: Balancing the Needs for Cytogenetic Testing With the Urgency of Treatment InitiationDr Erin Hurst and Dr Priyanka Mehta discuss striking the right balance between using cytogenetic testing to inform treatment decisions in patients with acute myeloid leukaemia and initiating treatment as soon as possible, and how to utilise the time between cytogenetic test and results effectively.
Topics
Cytogenetics
UK-VYX-2100032 | March 2021
-
3 mins
A New Era in Acute Myeloid Leukaemia (AML): The Importance of Cytogenetic TestingWatch as Prof. Nigel Russell talks about the importance of cytogenetic testing in treatment decision-making for patients with AML.
Topics
AML Landscape Cytogenetics
UK-VYX-2000173 | March 2021
-
10 mins
Integrating Cytogenetics in Acute Myeloid Leukaemia (AML) Decision-Making: A Case StudyDr Priyanka Mehta, Consultant Haematologist, and Dr Rachel Protheroe, Haematologist and Transplant Consultant, both from the University Hospitals Bristol discuss their approach in treating patients with AML and how cytogenetic testing has transformed this approach. While Consultant Clinical Scientist of the Bristol Genetics Laboratory, Dr Chris Wragg, gives an overview of the cytogenetic testing process in his lab and the changes he has implemented so results can be made available in a timely manner.
Topics
Cytogenetics
UK-VYX-2000174 | March 2021
-
8 mins
Vyxeos Liposomal: Practical InformationThis leaflet contains useful information on the indication and reimbursement status of Vyxeos Liposomal, as well as detailed instructions on how to prepare, store and administer the treatment.
Topics
Practicalities
UK-VYX-2100129 l June 2021
-
5 mins
Preparation and HandlingLearn how to prepare and store the Vyxeos Liposomal infusion with this video.
Topics
Practicalities
UK-VYX-2100028 | March 2021
-
10 mins
Vyxeos Liposomal: Patient InformationA simple guide to help patients understand everything they need to know about their treatment with Vyxeos Liposomal.
Topics
Practicalities Safety Vyxeos Liposomal Data
UK-VYX-2100144 l June 2021
-
4 mins
Mode of Action (MoA) and Phase III DataLearn about the MoA of Vyxeos Liposomal, as well as the Phase III data in high-risk* acute myeloid leukaemia (AML) patients.
Topics
Safety Vyxeos Liposomal Data
UK-VYX-2000172 | March 2021
